文献速递抗栓抗凝管理治疗药物监测与药物基因组学特殊人群用药

阿哌沙班药代动力学用于高风险老年患者剂量优化

Utilization of Apixaban Pharmacokinetics for Dose Optimization in High-Risk Elderly Patients.
PubMed 文献 · Clin Pharmacokinet · 2026-02-14

该回顾性观察性队列研究纳入127例住院老年患者,评估重复监测阿哌沙班血药浓度联合药代动力学分析和剂量调整对浓度及临床结局的影响。结果显示基于浓度监测的剂量调整增加了治疗范围内浓度患者比例,在高风险老年患者中浓度监测联合主动干预可能临床获益。

要点

  • 基线时16%患者阿哌沙班谷浓度低于治疗范围,20%高于治疗范围。
  • 女性与低于治疗范围浓度相关,标准剂量10 mg/日与高于治疗范围浓度相关。
  • 基于浓度监测的剂量调整可提高治疗范围内浓度患者比例。

核心结论

  • 基于阿哌沙班血药浓度监测的剂量调整增加了治疗范围内浓度患者比例。
  • 在高风险老年患者中,浓度监测联合主动干预可能临床获益,避免出血和血栓栓塞事件。

研究设计与样本

  • 回顾性观察性队列研究,在Hadassah Mount Scopus医院开展。
  • 纳入2020年1月至2024年9月住院的老年阿哌沙班处方患者,分析90天内两次适时的阿哌沙班最大血药浓度患者,共127例(中位年龄79岁,最大97岁;51%女性)。

主要发现

  • 基线时16%患者阿哌沙班血药浓度低于治疗范围,20%高于治疗范围。
  • 女性与低于治疗范围浓度相关,标准剂量(10 mg/日)阿哌沙班与高于治疗范围浓度相关。
  • 剂量调整在标准剂量治疗患者中更常见(调整OR 6.1,95%CI 2.2-16.9),在基线浓度超出范围患者中也更常见(调整OR 4.9,95%CI 1.9-12.7)。
  • 在重复测量最大血药浓度的患者中,第二次测量后1年随访内发生24例出血事件和6例血栓或栓塞事件。
  • 最大血药浓度超出治疗范围的患者出血事件更常见(28% vs 15%)。

临床怎么用

  • 在高风险老年患者中,可考虑监测阿哌沙班血药浓度并结合药代动力学分析进行剂量调整。
  • 对标准剂量治疗或基线浓度超出范围的患者,应关注剂量调整需求。
  • 浓度超出治疗范围与出血事件增加相关,应加强监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Direct oral anticoagulants have largely replaced vitamin K antagonists, for example, warfarin, because of their favorable safety profile and predictable pharmacokinetics, with apixaban being the most widely used direct oral anticoagulant. Although routine therapeutic drug monitoring is not required, measuring apixaban plasma concentrations may be useful in high-risk clinical scenarios. This aim of this study was to evaluate the impact of a repeat apixaban concentration measurement combined with a pharmacokinetic analysis and dose adjustment on drug concentrations and clinical outcomes. METHODS: We conducted a retrospective observational cohort study at Hadassah Mount Scopus Hospital, including elderly patients hospitalized between January 2020 and September 2024 with prescriptions for apixaban. Patients with two appropriately timed, maximum apixaban plasma concentrations within 90 days were analyzed. RESULTS: A total of 127 patients were included (median age 79 years, maximum age 97 years; 51% female). At baseline, 16% had subtherapeutic apixaban plasma concentrations and 20% had supratherapeutic concentrations. Female sex was associated with subtherapeutic concentrations while a standard dose (10 mg/day) of apixaban was associated with supratherapeutic plasma concentrations. Dose adjustment was more common in patients with standard dose therapy and in patients with an out-of-range baseline apixaban measurement with adjusted odds ratio of 6.1 and 95% confidence interval of 2.2-16.9 and 4.9 (95% confidence interval 1.9-12.7), respectively. In patients who had undergone repeated apixaban maximum plasma concentration measurements, we found 24 bleeding events and six thrombotic or embolic events within a 1-year follow-up from the second maximum plasma concentration measurement. Bleeding events were more common in patients whose maximum plasma concentration was out of the therapeutic range (28% vs 15%), CONCLUSIONS: Dose adjustment based on apixaban plasma concentration monitoring increased the proportion of patients who have apixaban concentrations within the therapeutic range. In high-risk elderly patients, an apixaban concentration measurement coupled with active intervention (e.g., dose adjustment) is likely to be clinically beneficial in avoiding bleeding and thromboembolic events.

来源:Clin Pharmacokinet,查看原文。版权归原作者所有。

引用

  1. Goldstein R, Sandouka K, Zighan L, et al. Utilization of Apixaban Pharmacokinetics for Dose Optimization in High-Risk Elderly Patients. Clin Pharmacokinet. 2026. PMID: 41689732. doi:10.1007/s40262-026-01625-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。